Virtus LifeSci Biotech Clinical Trials ETF (BBC)
| Assets | $10.66M |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | n/a |
| Dividend (ttm) | $0.08 |
| Dividend Yield | 0.34% |
| Ex-Dividend Date | Dec 20, 2023 |
| Payout Ratio | n/a |
| 1-Year Return | -1.09% |
| Volume | 4,115 |
| Open | 24.74 |
| Previous Close | 24.93 |
| Day's Range | 24.43 - 24.81 |
| 52-Week Low | 16.88 |
| 52-Week High | 28.74 |
| Beta | n/a |
| Holdings | 110 |
| Inception Date | Dec 16, 2014 |
About BBC
Fund Home PageThe Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is issued by Virtus Investment Partners.
Top 10 Holdings
13.99% of assets| Name | Symbol | Weight |
|---|---|---|
| Bny Mellon Cash Reserve Usd | n/a | 2.28% |
| RayzeBio, Inc. | RYZB | 1.91% |
| Cytokinetics, Incorporated | CYTK | 1.88% |
| Liquidia Corporation | LQDA | 1.38% |
| Karuna Therapeutics, Inc. | KRTX | 1.19% |
| Spyre Therapeutics Inc. | SYRE | 1.12% |
| RAPT Therapeutics, Inc. | RAPT | 1.06% |
| IGM Biosciences, Inc. | IGMS | 1.06% |
| Apogee Therapeutics, Inc. | APGE | 1.05% |
| ImmunityBio, Inc. | IBRX | 1.05% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 20, 2023 | $0.0823 | Dec 29, 2023 |
| Dec 20, 2017 | $0.29724 | Dec 27, 2017 |
| Dec 21, 2015 | $0.14733 | Dec 29, 2015 |
News
ALPS' Biotech ETF SBIO Week's Top Performer
In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way wit...
Biotech ETFs Are Making a Comeback
Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech ...
Biotech ETFs Strengthen as Bristol Myers Squibb Buys Turning Point
Biotechnology sector-related exchange traded funds were in a bright spot on Friday after Bristol Myers Squibb Co. (NYSE: BMY) said it will acquire drug developers Turning Point Therapeutics (NasdaqGS:...
Size Up SBIO as Biotech Catalysts Emerge
Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech ...
Betting on Biotech Bear Market Expiration Date
Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader...
Positioning for Biotech Bounceback
Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that...
Biotech Stocks, ETFs Starting to Look Healthier
Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALP...
SBIO Is a Good Place to Be for Biotech Innovation
While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare se...
Biotech M&A Could Finally Perk Up in 2022
Broadly speaking, mergers and acquisitions in the healthcare sector were steady in 2021, but for many investors, there weren't enough aimed at smaller biotechnology companies. As is often the case, ma...
Smaller Biotech Stocks Ready to Perk Up
If there's an asset class that's looking forward to 2022, it's small- and mid-cap (SMID) biotechnology stocks because that group dealt with a variety of headwinds this year. However, there are more re...
Biotech Stocks Have Colds, but They Can Heal
This year hasn't been kind to biotechnology stocks and related exchange traded funds. The headwinds faced by these assets were ratcheted up last week when the Biden administration revealed plans to pu...
Should Investors Follow Private Equity into Life Sciences?
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...
Betting on Biotech With Utility Beyond Covid-19
The ALPS Medical Breakthroughs ETF (SBIO) is one of many biotechnology ETF garnering attention this year amid the race to defeat the coronavirus, but SBIO also offers investors allure that will extend...
Novavax's 30% surge boosts biotech ETFs to best day in weeks
Exchange-traded funds with exposure to biotech stocks rocketed higher Tuesday on hopeful news about treatments for COVID-19.
Biotech ETFs Gain Amid Vaccine Optimism
With a slew of news to start off the month and quarter, biotech equities and ETFs are moving higher on Wednesday with optimism over developments on the coronavirus vaccine front. The Dow Jones Industr...
3 ETFs With Q2 Gains Of At Least 30%
The S&P 500 is sitting on an impressive 16.36% gain with just one day left in the second quarter.
Biotech ETFs in the Spotlight, Why They’ll Remain There
Biotechnology ETFs, including the ALPS Medical Breakthroughs ETF (SBIO), are on torrid paces in the second quarter. Yes, some of that bullishness is attributable to the industry’s efforts to vanquish ...
Biotechnology Sector ETFs Are Leading the Charge
Biotechnology sector-related exchange traded funds led the charge on Monday, with some breaking out to new highs. Among the best performing non-leveraged ETFs of Monday, the ARK Genomic Revolution ETF...
3 Biotech ETFs Up 10% Or More Over The Last Month
Something's been brewing in the health care sector, the second-largest group in the S&P 500.
Failure to Launch: The ETF Built to Fight the Coronavirus That Never Came to Be
Bloomberg's Eric Balchunas and Scarlet Fu break down the Virtus LifeSci Biotech Clinical Trials ETF (ticker: BBC) with Paul Yook, CIO of LifeSci Venture Partners.
Best Growth ETFs for Q1 2020
The best Growth ETFs for Q1 2020 are XLK, BBC, and VGT.
Best Healthcare ETFs for Q1 2020
The best Healthcare ETFs for Q1 2020 are BBC, SBIO, and KURE.
Biotech ETFs Are Not Riding the Wave from Coronavirus Panic
Despite concerns of a spreading coronavirus out of China, biotechnology stocks and sector-related ETFs are not enjoying the usual bump on hopes of developing new treatments to counter the contagion. A...
5 Best ETFs Of 2019
With just two trading days left in 2019, the SPDR S&P 500 ETF, the world's largest exchange traded fund, is higher by 29.19% this year, meaning the S&P 500 is on pace for its best annual performance s...